Ignite Creation Date:
2024-05-05 @ 6:35 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00504595
Status:
COMPLETED
Last Update Posted:
2012-08-07
First Post:
2007-07-19
Brief Title:
Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A 12-week Phase II Multi-center Randomized Double-blind Placebo-controlled Study to Assess the Response to Treatment ACR20 and to Determine a Biomarker Profile in Adult Patients With Established Rheumatoid Arthritis Responding to ACZ885 Anti-interleukin-1beta Monoclonal Antibody as Compared to Healthy Subjects Exposed to ACZ885
Status:
COMPLETED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was intended to assess the safety efficacy and response to treatment using the American College of Rheumatology ACR criteria of 20 improvement in symptoms ACR20 and to investigate a potential biomarker profile in adult patients with established rheumatoid arthritis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None